Physician profile
Namyi Yu
NPI 1831117399
$3,069.58
in general payments reported to CMS, 2019-2025
29 companies · $643 in 2025
The $643 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $995 · 2020: $317 · 2021: $395 · 2022: $253 · 2023: $360 · 2024: $106 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,025 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,024.70 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $553.30 | 2019-2025 | Zepbound, Jardiance, Baqsimi |
| Abbott Laboratories | $385.71 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $324.19 | 2019-2023 | |
| Novo Nordisk INC | $276.21 | 2019-2025 | Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $239.17 | 2019-2021 | |
| Amarin Pharma, INC. | $153.41 | 2019-2020 | |
| Amgen INC. | $106.77 | 2019-2025 | Tepezza, Evenity |
| Astrazeneca Pharmaceuticals LP | $106.55 | 2019-2021 | |
| Mannkind Corporation | $105.86 | 2025 | |
| Corcept Therapeutics | $93.34 | 2023-2024 | Korlym |
| Beta Bionics, INC. | $85.51 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Insmed, INC. | $81.68 | 2019 | |
| Amneal Pharmaceuticals LLC | $78.17 | 2019-2025 | Unithroid |
| Insulet Corporation | $73.06 | 2019-2023 | Omnipod |
| Dexcom, INC. | $57.89 | 2023 | Dexcom G6 Transmitter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $55.29 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.02 | 2019-2025 | Jardiance |
| Lifescan, INC. | $36.07 | 2019-2020 | |
| Horizon Therapeutics Plc | $31.45 | 2023 | Tepezza |
| Alexion Pharmaceuticals, INC. | $27.47 | 2025 | Strensiq |
| Xeris Pharmaceuticals, INC. | $23.65 | 2021 | |
| Medtronic, INC. | $16.98 | 2021 | |
| Chiesi USA, INC. | $16.75 | 2025 | Myalept |
| Currax Pharmaceuticals LLC | $16.28 | 2025 | Contrave |
| Recordati_rare_diseases_inc. | $15.97 | 2025 | Isturisa |
| Echosens North America, INC. | $15.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.56 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.23 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Namyi Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.